The application of selective reaction monitoring confirms dysregulation of glycolysis in a preclinical model of schizophrenia

BMC Research Notes

Volumn 5, Issue , 2012, Pages

  Martins De Souza, Daniel ^a   Alsaif, Murtada ^a   Ernst, Agnes ^a   Harris, Laura W ^a   Aerts, Nancy ^b   Lenaerts, Ilse ^b   Peeters, Pieter J ^b   Amess, Bob ^a   Rahmoune, Hassan ^a   Bahn, Sabine ^a,c   Guest, Paul C ^a  

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^b JANSSEN RESEARCH AND DEVELOPMENT   (Belgium)

^c ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

Assay; Glycolysis; MRM; Multiple reaction monitoring; Multiplex; Preclinical; Proteomics; Schizophrenia; Selective reaction monitoring; SRM

Indexed keywords

RATTUS;

ENOLASE; FRUCTOSE BISPHOSPHATE ALDOLASE; GLYCERALDEHYDE 3 PHOSPHATE DEHYDROGENASE; HEXOKINASE; PHENCYCLIDINE; PHOSPHOGLYCERATE KINASE; PHOSPHOGLYCERATE MUTASE; TRIOSEPHOSPHATE ISOMERASE;

ANIMAL; ARTICLE; CHEMICALLY INDUCED DISORDER; DISEASE MODEL; DRUG ANTAGONISM; DRUG EFFECT; ENZYMOLOGY; FRONTAL LOBE; GLYCOLYSIS; HUMAN; MALE; METABOLISM; MULTIVARIATE ANALYSIS; PATHOPHYSIOLOGY; PHYSIOLOGY; RAT; SCHIZOPHRENIA;

ANIMALS; DISEASE MODELS, ANIMAL; FRONTAL LOBE; FRUCTOSE-BISPHOSPHATE ALDOLASE; GLYCERALDEHYDE-3-PHOSPHATE DEHYDROGENASES; GLYCOLYSIS; HEXOKINASE; HUMANS; MALE; METABOLIC NETWORKS AND PATHWAYS; MULTIVARIATE ANALYSIS; PHENCYCLIDINE; PHOSPHOGLYCERATE KINASE; PHOSPHOGLYCERATE MUTASE; PHOSPHOPYRUVATE HYDRATASE; RATS; SCHIZOPHRENIA; TRIOSE-PHOSPHATE ISOMERASE;

EID: 84858114881     PISSN: None     EISSN: 17560500     Source Type: Journal    
DOI: 10.1186/1756-0500-5-146     Document Type: Article

References (41)

1. Schizophrenia. Freedman R, N Engl J Med 2003 349 18 1738 1749 10.1056/NEJMra035458 14585943 (Pubitemid 37315012)
2. Animal models of schizophrenia. Young JW, Zhou X, Geyer MA, Curr Top Behav Neurosci 2010 4 391 433 10.1007/7854-2010-62 21312408
3. Thinking glutamatergically: changing concepts of schizophrenia based upon changing neurochemical models. Kantrowitz JT, Javitt DC, Clin Schizophr Relat Psychoses 2010 4 3 189 200 10.3371/CSRP.4.3.6 20880830
4. Delayed regional metabolic actions of phencyclidine. Gao XM, Shirakawa O, Du F, Tamminga CA, Eur J Pharmacol 1993 241 1 7 15 10.1016/0014-2999(93)90926-9 8223927 (Pubitemid 23268330)
5. Neurochemical changes in the rat prefrontal cortex following acute phencyclidine treatment: an in vivo localized (1)H MRS study. Iltis I, Koski DM, Eberly LE, Nelson CD, Deelchand DK, Valette J, Ugurbil K, Lim KO, Henry PG, NMR Biomed 2009 22 7 737 744 10.1002/nbm.1385 19338025
6. The use of PET imaging in studying cognition, genetics and pharmacotherapeutic interventions in schizophrenia. Vyas NS, Patel NH, Nijran KS, Al-Nahhas A, Puri BK, Expert Rev Neurother 2011 11 1 37 51 10.1586/ern.10.160 21158554
7. Analyzing schizophrenia by DNA microarrays. Horvath S, Janka Z, Mirnics K, Biol Psychiatry 2011 69 2 157 162 10.1016/j.biopsych.2010.07.017 20801428
8. RNA Biomarkers in Schizophrenia. Martins De-Souza D, Dias-Neto E, Biomarkers for Psychiatric Disorders Turck CW: Springer 1 2009 97 127
9. Proteome analysis of schizophrenia brain tissue. Martins-De-Souza D, Dias-Neto E, Schmitt A, Falkai P, Gormanns P, Maccarrone G, Turck CW, Gattaz WF, World J Biol Psychiatry 2010 11 2 110 120 10.3109/15622970903490626 20109112
10. The neuroproteomics of schizophrenia. English JA, Pennington K, Dunn MJ, Cotter DR, Biol Psychiatry 2011 69 2 163 172 10.1016/j.biopsych.2010.06.031 20887976
11. The role of energy metabolism dysfunction and oxidative stress in schizophrenia revealed by proteomics. Martins-de-Souza D, Harris LW, Guest PC, Bahn S, Antioxid Redox Signal 2011 15 7 2067 2079 10.1089/ars.2010.3459 20673161
12. KEGG: kyoto encyclopedia of genes and genomes. Kanehisa M, Goto S, Nucleic Acids Res 2000 28 1 27 30 10.1093/nar/28.1.27 10592173 (Pubitemid 30047706)
13. Thalamic abnormalities in schizophrenia visualized through magnetic resonance image averaging. Andreasen NC, Arndt S, Swayze V, Cizadlo T, Flaum M, O'Leary D, Ehrhardt JC, Yuh WT, Science 1994 266 5183 294 298 10.1126/science.7939669 7939669 (Pubitemid 24343518)
14. Age- and dose-dependent glucose-induced increases in memory and attention in schizophrenia. Fucetola R, Newcomer JW, Craft S, Melson AK, Psychiatry Res 1999 88 1 1 13 10.1016/S0165-1781(99)00063-3 10641582 (Pubitemid 29494963)
15. Limbic system abnormalities identified in schizophrenia using positron emission tomography with fluorodeoxyglucose and neocortical alterations with deficit syndrome. Tamminga CA, Thaker GK, Buchanan R, Kirkpatrick B, Alphs LD, Chase TN, Carpenter WT, Arch Gen Psychiatry 1992 49 7 522 530 10.1001/archpsyc.1992.01820070016003 1627043
16. Mitochondrial dysfunction and psychiatric disorders. Rezin GT, Amboni G, Zugno AI, Quevedo J, Streck EL, Neurochem Res 2009 34 6 1021 1029 10.1007/s11064-008-9865-8 18979198
17. Identification of proteomic signatures associated with depression and psychotic depression in post-mortem brains from major depression patients. Martins-de-Souza D, Guest PC, Harris LW, Vanattou-Saifoudine N, Webster MJ, Rahmoune H, Bahn S, Transl Psychiatry 2012 2 87 10.1038/tp.2012.13
18. Can proteomics retire the western blot? Mann M, J Proteome Res 2008 7 8 3065 10.1021/pr800463v 18671370
19. Mitochondrial dysfunction in schizophrenia: evidence for compromised brain metabolism and oxidative stress. Prabakaran S, Swatton JE, Ryan MM, Huffaker SJ, Huang JT, Griffin JL, Wayland M, Freeman T, Dudbridge F, Lilley KS, et al. Mol Psychiatry 2004 9 7 684 697. 643 15098003 (Pubitemid 38932173)
20. Proteomic analysis of dorsolateral prefrontal cortex indicates the involvement of cytoskeleton, oligodendrocyte, energy metabolism and new potential markers in schizophrenia. Martins-de-Souza D, Gattaz WF, Schmitt A, Maccarrone G, Hunyadi-Gulyas E, Eberlin MN, Souza GH, Marangoni S, Novello JC, Turck CW, et al. J Psychiatr Res 2009 43 11 978 986 10.1016/j.jpsychires.2008. 11.006 19110265
21. Disease-specific alterations in frontal cortex brain proteins in schizophrenia, bipolar disorder, and major depressive disorder. The Stanley Neuropathology Consortium. Johnston-Wilson NL, Sims CD, Hofmann JP, Anderson L, Shore AD, Torrey EF, Yolken RH, Mol Psychiatry 2000 5 2 142 149 10.1038/sj.mp.4000696 10822341 (Pubitemid 30229428)
22. The discovery of susceptibility genes for mental disorders. Cloninger CR, Proc Natl Acad Sci USA 2002 99 21 13365 13367 10.1073/pnas.222532599 12374853 (Pubitemid 35215383)
23. Gene-environment interactions in schizophrenia: review of epidemiological findings and future directions. van Os J, Rutten BP, Poulton R, Schizophr Bull 2008 34 6 1066 1082 10.1093/schbul/sbn117 18791076
24. Schizophrenia: the polygene princess and the pea. Collier DA, Psychol Med 2008 38 12 1687 1691 discussion 1818-1620 10.1017/S0033291708003668 18590580
25. "Critical Path" is on the road forward; FDA reports industry activity is high. Marson B, The Pink Sheet 2007 69 29
26. Funding for accelerating drug development initiative critical. Owens J, Nat Rev Drug Discov 2006 5 4 271 10.1038/nrd2015 16628830
27. Proteomics beyond proteomics: toward clinical applications. Plymoth A, Hainaut P, Curr Opin Oncol 2011 23 1 77 82 10.1097/CCO.0b013e32834179c1 21107258
28. A liquid-liquid LC/MS/MS assay for the determination of artemether and DHA in malaria patient samples. Wiesner L, Govender K, Meredith SA, Norman J, Smith PJ, J Pharm Biomed Anal 2011 55 2 373 378 10.1016/j.jpba.2011.01.036 21353430
29. Simultaneous quantification of apolipoprotein A-I and apolipoprotein B by liquid-chromatography-multiple- reaction-monitoring mass spectrometry. Agger SA, Marney LC, Hoofnagle AN, Clin Chem 2010 56 12 1804 1813 10.1373/clinchem. 2010.152264 20923952
30. Targeted in-gel MRM: a hypothesis driven approach for colorectal cancer biomarker discovery in human feces. Ang CS, Nice EC, J Proteome Res 2010 9 9 4346 4355 10.1021/pr100509e 20684568
31. Scoring proteomes with proteotypic peptide probes. Kuster B, Schirle M, Mallick P, Aebersold R, Nat Rev Mol Cell Biol 2005 6 7 577 583 10.1038/nrm1683 15957003 (Pubitemid 40943048)
32. Global absolute quantification of a proteome: Challenges in the deployment of a QconCAT strategy. Brownridge P, Holman SW, Gaskell SJ, Grant CM, Harman VM, Hubbard SJ, Lanthaler K, Lawless C, O'Cualain R, Sims P, et al. Proteomics 2011 11 15 2957 2970 10.1002/pmic.201100039 21710569
33. PHOSIDA 2011: the posttranslational modification database. Gnad F, Gunawardena J, Mann M, Nucleic Acids Res 2011 39 253 260 10.1093/nar/gkq1159
34. Mouse behavioral endophenotypes for schizophrenia. Amann LC, Gandal MJ, Halene TB, Ehrlichman RS, White SL, McCarren HS, Siegel SJ, Brain Res Bull 2010 83 3-4 147 161 10.1016/j.brainresbull.2010.04.008 20433908
35. Animal models of cognitive dysfunction and negative symptoms of schizophrenia: focus on NMDA receptor antagonism. Neill JC, Barnes S, Cook S, Grayson B, Idris NF, McLean SL, Snigdha S, Rajagopal L, Harte MK, Pharmacol Ther 2010 128 3 419 432 10.1016/j.pharmthera.2010.07.004 20705091
36. Comparison between intraperitoneal and subcutaneous phencyclidine administration in Sprague-Dawley rats: a locomotor activity and gene induction study. Kalinichev M, Robbins MJ, Hartfield EM, Maycox PR, Moore SH, Savage KM, Austin NE, Jones DN, Prog Neuropsychopharmacol Biol Psychiatry 2008 32 2 414 422 10.1016/j.pnpbp.2007.09.008 17945407 (Pubitemid 351178957)
37. The use of ASB-14 in combination with CHAPS is the best for solubilization of human brain proteins for two-dimensional gel electrophoresis. Martins-de-Souza DE, Menezes-de-Oliveira B, Dos-Santos Farias A, Horiuchi RS, Crepaldi Domingues C, De-Paula E, Marangoni S, Gattaz WF, Dias-Neto E, Camillo Novello J, Brief Funct Genomic Proteomic 2007 6 1 70 75 10.1093/bfgp/elm009 17556486 (Pubitemid 351721049)
38. Skyline: an open source document editor for creating and analyzing targeted proteomics experiments. MacLean B, Tomazela DM, Shulman N, Chambers M, Finney GL, Frewen B, Kern R, Tabb DL, Liebler DC, MacCoss MJ, Bioinformatics 2010 26 7 966 968 10.1093/bioinformatics/btq054 20147306
39. Identification of a biological signature for schizophrenia in serum. Schwarz E, Guest PC, Rahmoune H, Harris LW, Wang L, Leweke FM, Rothermundt M, Bogerts B, Koethe D, Kranaster L, et al. Mol Psychiatry 2011 doi:10.1038/mp.2011.42
40. PLS discriminant analysis applied to conventional sensory profiling data. Rossinia KVS, Carioua V, Qannaria EM, Fogliatto FS, Food Quality and Preference 2012 23 18 24 10.1016/j.foodqual.2011.01.005
41. Using LC-oa-TOF MSE with a Multivariate Statistical Sample Statistical Sample Profiling Strategy to Distinguish Chinese Red Ginseng from Korean Red Ginseng. http://chromatographyonline.findanalytichem.com/lcgc/article/ articleDetail.jsp?id=632624&sk=&date=&pageID=5